课题基金 / 基金详情

Replicative stress as a primary determinant of chemotherapeutic outcome in ovarian cancer

Replicative stress as a primary determinant of chemotherapeutic outcome in ovarian cancer
复制应激是卵巢癌化疗结果的主要决定因素
批准号：
450765
负责人：
Drobetsky Elliot A
金额：
$67.71万
依托单位：
CIUSSS Est-de-l'Ile-de- Montral-Maisonneuve Rosemont
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
未结题
起止时间：
2021-09-01 至 2026-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=450765&lang=en
关键词：
Chemoresistance Dna Damage Signaling Dna Double Strand Break Repair Dna Replication Stress Nucleotide Excision Repair Ovarian Cancer

项目摘要

项目成果

Drobetsky Elliot A的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
According to the Canadian Cancer Society, this past year an estimated 3000 Canadian women were diagnosed with ovarian cancer and 1900 succumbed to this deadly disease.Chemotherapeutic drugs used to treat ovarian cancer can initially be extremely effective
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A novel mechanism of chemoresistance in ovarian cancer cells
Regulation of UV Damage Repair by the ATR-mediated DNA Damage Checkpoint in Malignant Melanoma
海外基金